Scholarlink

Background <p>Secondary hyperparathyroidism (SHPT) is a common complication of chronic kidney disease–mineral and bone disorder (CKD-MBD) in patients receiving maintenance hemodialysis. Genetic and epigenetic regulators of mineral metabolism, including Klotho gene polymorphisms and microRNAs, have emerged as potential contributors to disease susceptibility; however, their clinical relevance remains incompletely defined. This study investigated the association of the Klotho rs1207568 polymorphism and serum microRNA-192 (miR-192) expression with SHPT in Egyptian hemodialysis patients.</p> Methods <p>This case–control study included 200 maintenance hemodialysis patients (100 with SHPT and 100 without SHPT) and 100 healthy controls. SHPT was defined as intact parathyroid hormone (iPTH) &gt; 65 pg/mL. Genotyping of Klotho rs1207568 was performed using TaqMan real-time PCR, and serum miR-192 expression was quantified by qRT-PCR. Clinical and biochemical parameters were compared across genotype groups. Multivariable logistic and linear regression analyses were conducted with adjustment for age, sex, dialysis duration, diabetes status, serum calcium, and phosphate.</p> Results <p>The AA genotype and A allele of Klotho rs1207568 were significantly more frequent in hemodialysis patients with SHPT. In adjusted analyses, the A allele was independently associated with increased odds of SHPT (OR = 2.37,<i>p</i> &lt; 0.001). Serum miR-192 expression was significantly downregulated in SHPT patients compared with non-SHPT patients and healthy controls (<i>p</i> &lt; 0.001). Lower miR-192 expression remained independently associated with SHPT after multivariable adjustment (β = −2.786, <i>p</i> &lt; 0.001). Receiver operating characteristic analysis demonstrated moderate diagnostic performance of miR-192 for SHPT (AUC = 0.751).</p> Conclusion <p>Klotho rs1207568 polymorphism and reduced serum miR-192 expression are independently associated with SHPT in Egyptian maintenance hemodialysis patients. These findings suggest that genetic variation in Klotho and epigenetic regulation via miR-192 may contribute to disordered mineral metabolism in end-stage kidney disease. Further large-scale studies with comprehensive CKD-MBD phenotyping are warranted.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Association of Klotho gene polymorphism (rs1207568) and serum miR-192 expression with secondary hyperparathyroidism in Egyptian hemodialysis patients

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月8日

查看全文
  • Doaa Mamdouh Aly,
  • Asmaa Mohamed Fteah,
  • Samia El-Shishtawy,
  • Nevine Sherif

摘要

Background

Secondary hyperparathyroidism (SHPT) is a common complication of chronic kidney disease–mineral and bone disorder (CKD-MBD) in patients receiving maintenance hemodialysis. Genetic and epigenetic regulators of mineral metabolism, including Klotho gene polymorphisms and microRNAs, have emerged as potential contributors to disease susceptibility; however, their clinical relevance remains incompletely defined. This study investigated the association of the Klotho rs1207568 polymorphism and serum microRNA-192 (miR-192) expression with SHPT in Egyptian hemodialysis patients.

Methods

This case–control study included 200 maintenance hemodialysis patients (100 with SHPT and 100 without SHPT) and 100 healthy controls. SHPT was defined as intact parathyroid hormone (iPTH) > 65 pg/mL. Genotyping of Klotho rs1207568 was performed using TaqMan real-time PCR, and serum miR-192 expression was quantified by qRT-PCR. Clinical and biochemical parameters were compared across genotype groups. Multivariable logistic and linear regression analyses were conducted with adjustment for age, sex, dialysis duration, diabetes status, serum calcium, and phosphate.

Results

The AA genotype and A allele of Klotho rs1207568 were significantly more frequent in hemodialysis patients with SHPT. In adjusted analyses, the A allele was independently associated with increased odds of SHPT (OR = 2.37,p < 0.001). Serum miR-192 expression was significantly downregulated in SHPT patients compared with non-SHPT patients and healthy controls (p < 0.001). Lower miR-192 expression remained independently associated with SHPT after multivariable adjustment (β = −2.786, p < 0.001). Receiver operating characteristic analysis demonstrated moderate diagnostic performance of miR-192 for SHPT (AUC = 0.751).

Conclusion

Klotho rs1207568 polymorphism and reduced serum miR-192 expression are independently associated with SHPT in Egyptian maintenance hemodialysis patients. These findings suggest that genetic variation in Klotho and epigenetic regulation via miR-192 may contribute to disordered mineral metabolism in end-stage kidney disease. Further large-scale studies with comprehensive CKD-MBD phenotyping are warranted.